Home / Publications



"Evaluation of azacitidine in transfusion-dependent, Epo-refractory patients with lower-risk MDS". Tobiasson M, Brandefors L, Dybedahl I, Garelius H, Grovdal M et al.  17 Congress of the EHA, 2012, Abstr. nor.:1381


"Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities". Mollgard L, Saft L, Bach Treppendahl M, Dybedal I, Norgaard J M et al.  Haematologica, 2011:96(7);963-971.


"Significance of JAK2 and TET2 mutations in myelodysplastic syndromes". Hellstrom-Lindberg. Blood Reviews 24(2010);83-90

"Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy". Grovdal et al.  British Journal of Haematology,150;293-302


"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study". Fenaux et al. LancetOncology; vol10, March2009;223-232


"Supportive care, growth factors, and new therapies in myelodysplastic syndromes". Eva Hellstrom-Lindberg, Luca Malcovati. Blood Reviews (2008)22;75–91

"Erythropoietin and G-CSF Treatment Associated with Improved Survival in Myelodysplastic Syndrome ". Martin Jädersten, Luca Malcovati et al.  JCO2008


"Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and AcuteMyeloid Leukemia following Myelodysplastic Syndrome". Michael Grovdal et al.  Clin Cancer Res 2007;7107-7112 13(23) December 1, 2007


"Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes". P.A. Broliden et al. Haematologica 2006;91:667-670


»» Long term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. M Jädersten, Scott M. Montgomery, Ingunn Dybedal, Anna Porwit-MacDonald and Eva Hellström-Lindberg . Clinical observations, interventions and therapeutic trials. Blood 1 August 2005.Volym 106, Number 3.

application/pdf Jadersten BLOOD 351.67 kB


»» The WHO classification of MDS does make a difference. Robert B.Howe, Anna Porwit-McDonald,Robert Wanat, Ramin Tehranchi and Eva Hellström-Lindberg. Blood May 1 2004. Volume 103, Number 9. 

Article for download Howe.pdf 188.07 kB


»» No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Robert Hast et al. Leukemia 2003

Article for download Hast2003.pdf 136.57 kB

»» A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony stimulating factor: significant effects on quality of life. Eva Hellström-Lindberg et al. British Journal of Hematology, 2003

Last update: 2008-08-10 |  Go Back |  Print View